Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 2,774 shares, a decline of 83.3% from the August 15th total of 16,627 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. Approximately 0.0% of the company’s stock are sold short.
Innate Pharma Price Performance
OTCMKTS IPHYF remained flat at $1.65 on Friday. The business has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $1.71. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
See Also
- Five stocks we like better than Innate Pharma
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
